top of page

With an experienced researcher at the helm, Seoul-based Theragen Bio aims to leverage its sequencing and bioinformatics expertise to also develop cancer therapies

  • blonca9
  • Nov 24, 2024
  • 1 min read

CEO Soon Paik, who was a developer Oncotype Dx and the founding director of Samsung Cancer Research Institute, discusses Theragen's sequencing and bioinformatics business and how he hopes to develop cancer vaccines and targeted therapies such as against MAPK3.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Genezen_Logo_RGB.png

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

bottom of page